{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:23:26Z","timestamp":1782962606327,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10067-024-07029-9","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T19:01:28Z","timestamp":1718391688000},"page":"2513-2520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of belimumab on the lipid profile in systemic lupus erythematosus patients: an observational study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6649-3122","authenticated-orcid":false,"given":"Di","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-503X","authenticated-orcid":false,"given":"Rui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"7029_CR1","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/aitc202006020","volume":"172","author":"M Kiriakidou","year":"2020","unstructured":"Kiriakidou M, Ching CL (2020) Systemic lupus erythematosus. Ann Intern Med 172:ITC81\u2013ITC96. https:\/\/doi.org\/10.7326\/aitc202006020","journal-title":"Ann Intern Med"},{"key":"7029_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","volume":"43","author":"SR Schoenfeld","year":"2013","unstructured":"Schoenfeld SR, Kasturi S, Costenbader KH (2013) The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 43:77\u201395. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.12.002","journal-title":"Semin Arthritis Rheum"},{"key":"7029_CR3","doi-asserted-by":"publisher","unstructured":"Fors Nieves CE, Izmirly PM (2016) Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep 18.https:\/\/doi.org\/10.1007\/s11926-016-0571-2","DOI":"10.1007\/s11926-016-0571-2"},{"key":"7029_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s10067-023-06539-2","volume":"42","author":"S Huang","year":"2023","unstructured":"Huang S, Zhang Z, Cui Y, Yao G, Ma X, Zhang H (2023) Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus. Clin Rheumatol 42:1565\u20131572. https:\/\/doi.org\/10.1007\/s10067-023-06539-2","journal-title":"Clin Rheumatol"},{"key":"7029_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/biom13030401","volume":"13","author":"\u00c1 Di\u00f3szegi","year":"2023","unstructured":"Di\u00f3szegi \u00c1, L\u0151rincz H, Ka\u00e1li E et al (2023) Role of altered metabolism of triglyceride-rich lipoprotein particles in the development of vascular dysfunction in systemic lupus erythematosus. Biomolecules 13:401. https:\/\/doi.org\/10.3390\/biom13030401","journal-title":"Biomolecules"},{"key":"7029_CR6","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s10067-018-4051-0","volume":"37","author":"AM Atta","year":"2018","unstructured":"Atta AM, Silva JPCG, Santiago MB, Oliveira IS, Oliveira RC, Sousa Atta MLB (2018) Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus. Clin Rheumatol 37:1539\u20131546. https:\/\/doi.org\/10.1007\/s10067-018-4051-0","journal-title":"Clin Rheumatol"},{"key":"7029_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/096120339700600610","volume":"6","author":"EF Borba","year":"2016","unstructured":"Borba EF, Bonf\u00e1 E (2016) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533\u2013539. https:\/\/doi.org\/10.1177\/096120339700600610","journal-title":"Lupus"},{"key":"7029_CR8","doi-asserted-by":"publisher","unstructured":"Robinson G, Pineda-Torra I, Ciurtin C, Jury EC (2022) Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. J Clin Investig 132.https:\/\/doi.org\/10.1172\/jci148552","DOI":"10.1172\/jci148552"},{"key":"7029_CR9","doi-asserted-by":"publisher","unstructured":"Hasni SA, Gupta S, Davis M et al (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun 12.https:\/\/doi.org\/10.1038\/s41467-021-23361-z","DOI":"10.1038\/s41467-021-23361-z"},{"key":"7029_CR10","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/1521-4141(200207)32:7<2004::aid-immu2004>3.0.co;2-5","volume":"32","author":"AG Rolink","year":"2002","unstructured":"Rolink AG, Tschopp J, Schneider P, Melchers F (2002) BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 32:2004. https:\/\/doi.org\/10.1002\/1521-4141(200207)32:7%3c2004::aid-immu2004%3e3.0.co;2-5","journal-title":"Eur J Immunol"},{"key":"7029_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1084\/jem.192.10.1453","volume":"192","author":"M Batten","year":"2000","unstructured":"Batten M, Groom J, Cachero TG et al (2000) Baff mediates survival of peripheral immature B lymphocytes. J Exp Med 192:1453\u20131466. https:\/\/doi.org\/10.1084\/jem.192.10.1453","journal-title":"J Exp Med"},{"key":"7029_CR12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri M, Orr\u00f9 V, Idda ML et al (2017) Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med 376:1615\u20131626. https:\/\/doi.org\/10.1056\/NEJMoa1610528","journal-title":"N Engl J Med"},{"key":"7029_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1161\/atvbaha.112.300112","volume":"33","author":"T Huan","year":"2013","unstructured":"Huan T, Zhang B, Wang Z et al (2013) A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol 33:1427\u20131434. https:\/\/doi.org\/10.1161\/atvbaha.112.300112","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7029_CR14","doi-asserted-by":"publisher","first-page":"e29371","DOI":"10.1371\/journal.pone.0029371","volume":"7","author":"HHHW Schmidt","year":"2012","unstructured":"Schmidt HHHW, Kyaw T, Tay C et al (2012) Depletion of B2 but Not B1a B cells in BAFF receptor-deficient ApoE\u2212\/\u2212 mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS ONE 7:e29371. https:\/\/doi.org\/10.1371\/journal.pone.0029371","journal-title":"PLoS ONE"},{"key":"7029_CR15","doi-asserted-by":"publisher","first-page":"e60430","DOI":"10.1371\/journal.pone.0060430","volume":"8","author":"MM Heimesaat","year":"2013","unstructured":"Heimesaat MM, Kyaw T, Cui P et al (2013) BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE\u2212\/\u2212 mice. PLoS ONE 8:e60430. https:\/\/doi.org\/10.1371\/journal.pone.0060430","journal-title":"PLoS ONE"},{"key":"7029_CR16","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.4049\/jimmunol.1601198","volume":"197","author":"SW Jackson","year":"2016","unstructured":"Jackson SW, Scharping NE, Jacobs HM, Wang S, Chait A, Rawlings DJ (2016) Cutting edge: BAFF overexpression reduces atherosclerosis via TACI-dependent B cell activation. J Immunol 197:4529\u20134534. https:\/\/doi.org\/10.4049\/jimmunol.1601198","journal-title":"J Immunol"},{"key":"7029_CR17","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/circulationaha.117.032790","volume":"138","author":"D Tsiantoulas","year":"2018","unstructured":"Tsiantoulas D, Sage AP, G\u00f6derle L et al (2018) B cell\u2013activating factor neutralization aggravates atherosclerosis. Circulation 138:2263\u20132273. https:\/\/doi.org\/10.1161\/circulationaha.117.032790","journal-title":"Circulation"},{"key":"7029_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/art.41485","volume":"73","author":"F Saidoune","year":"2020","unstructured":"Saidoune F, Even G, Lamri Y et al (2020) Effects of BAFF neutralization on atherosclerosis associated with systemic lupus erythematosus. Arthritis Rheumatol 73:255\u2013264. https:\/\/doi.org\/10.1002\/art.41485","journal-title":"Arthritis Rheumatol"},{"key":"7029_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3858\/emm.2009.41.3.024","volume":"41","author":"Y-H Kim","year":"2009","unstructured":"Kim Y-H, Choi B-H, Cheon H-G, Do M-S (2009) B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation. Exp Mol Med 41:208. https:\/\/doi.org\/10.3858\/emm.2009.41.3.024","journal-title":"Exp Mol Med"},{"key":"7029_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/life12050634","volume":"12","author":"DCV S\u00e1nchez","year":"2022","unstructured":"S\u00e1nchez DCV, Castellanos SG, Sandoval MEV, Garc\u00eda AG (2022) B-cell activating factor increases related to adiposity, insulin resistance, and endothelial dysfunction in overweight and obese subjects. Life 12:634. https:\/\/doi.org\/10.3390\/life12050634","journal-title":"Life"},{"key":"7029_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae192","author":"A-G Dedemadi","year":"2024","unstructured":"Dedemadi A-G, Gkolfinopoulou C, Nikoleri D et al (2024) Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keae192","journal-title":"Rheumatology"},{"key":"7029_CR22","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai A-M, Alarc\u00f3n GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"key":"7029_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3899\/jrheum.150983","volume":"43","author":"MB Urowitz","year":"2016","unstructured":"Urowitz MB, Iba\u00f1ez D, Su J, Gladman DD (2016) Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol 43:875\u2013879. https:\/\/doi.org\/10.3899\/jrheum.150983","journal-title":"J Rheumatol"},{"key":"7029_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1023\/B:EJEP.0000036572.00663.f2","volume":"19","author":"JWR Twisk","year":"2003","unstructured":"Twisk JWR (2003) Longitudinal data analysis. a comparison between generalized estimating equations and random coefficient analysis. Eur J Epidemiol 19:769\u2013776. https:\/\/doi.org\/10.1023\/B:EJEP.0000036572.00663.f2","journal-title":"Eur J Epidemiol"},{"key":"7029_CR25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/rheumatology\/kep446","volume":"49","author":"JM Pego-Reigosa","year":"2010","unstructured":"Pego-Reigosa JM, Lu TYT, Fontanillo MF, Campo-Perez Vd, Rahman A, Isenberg DA (2010) Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology 49:691\u2013696. https:\/\/doi.org\/10.1093\/rheumatology\/kep446","journal-title":"Rheumatology"},{"key":"7029_CR26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/0961203314534909","volume":"23","author":"A Fern\u00e1ndez-Nebro","year":"2014","unstructured":"Fern\u00e1ndez-Nebro A, Marenco JL, L\u00f3pez-Longo F et al (2014) The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). Lupus 23:1014\u20131022. https:\/\/doi.org\/10.1177\/0961203314534909","journal-title":"Lupus"},{"key":"7029_CR27","doi-asserted-by":"publisher","unstructured":"Singh JA, Shah NP, Mudano AS (2021) Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev 2021.https:\/\/doi.org\/10.1002\/14651858.CD010668.pub2","DOI":"10.1002\/14651858.CD010668.pub2"},{"key":"7029_CR28","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","volume":"9","author":"SP Huang","year":"2022","unstructured":"Huang SP, Snedecor SJ, Nanji S, Lloyd E, Bell CF (2022) Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review. Rheumatol Ther 9:975\u2013991. https:\/\/doi.org\/10.1007\/s40744-022-00454-9","journal-title":"Rheumatol Ther"},{"key":"7029_CR29","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/art.24677","volume":"60","author":"M McMahon","year":"2009","unstructured":"McMahon M, Grossman J, Skaggs B et al (2009) Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 60:2428\u20132437. https:\/\/doi.org\/10.1002\/art.24677","journal-title":"Arthritis Rheum"},{"key":"7029_CR30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2016-209683","volume":"76","author":"CK Smith","year":"2017","unstructured":"Smith CK, Seto NL, Vivekanandan-Giri A et al (2017) Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. Ann Rheum Dis 76:602\u2013611. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209683","journal-title":"Ann Rheum Dis"},{"key":"7029_CR31","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1186\/ar3020","volume":"12","author":"JMP Woo","year":"2010","unstructured":"Woo JMP, Lin Z, Navab M et al (2010) Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 12:R93. https:\/\/doi.org\/10.1186\/ar3020","journal-title":"Arthritis Res Ther"},{"key":"7029_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.cir.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ et al (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8\u201315. https:\/\/doi.org\/10.1161\/01.cir.79.1.8","journal-title":"Circulation"},{"key":"7029_CR33","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/art.10542","volume":"46","author":"J Delgado Alves","year":"2002","unstructured":"Delgado Alves J, Ames PRJ, Donohue S et al (2002) Antibodies to high-density lipoprotein and \u03b22-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686\u20132694. https:\/\/doi.org\/10.1002\/art.10542","journal-title":"Arthritis Rheum"},{"key":"7029_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/ken397","volume":"48","author":"JR Batuca","year":"2008","unstructured":"Batuca JR, Ames PRJ, Amaral M, Favas C, Isenberg DA, Delgado Alves J (2008) Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology 48:26\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/ken397","journal-title":"Rheumatology"},{"key":"7029_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27764","volume":"63","author":"R Srivastava","year":"2010","unstructured":"Srivastava R, Yu S, Parks BW, Black LL, Kabarowski JH (2010) Autoimmune-mediated reduction of high-density lipoprotein\u2013cholesterol and paraoxonase 1 activity in systemic lupus erythematosus\u2013prone gld mice. Arthritis Rheum 63:201\u2013211. https:\/\/doi.org\/10.1002\/art.27764","journal-title":"Arthritis Rheum"},{"key":"7029_CR36","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/art.11264","volume":"48","author":"E Svenungsson","year":"2003","unstructured":"Svenungsson E, Gunnarsson I, Fei G-Z, Lundberg IE, Klareskog L, Frosteg\u00e5rd J (2003) Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor \u03b1\/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533\u20132540. https:\/\/doi.org\/10.1002\/art.11264","journal-title":"Arthritis Rheum"},{"key":"7029_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0002-9343(87)90762-5","volume":"83","author":"WH Ettinger","year":"1987","unstructured":"Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Am J Med 83:503\u2013508. https:\/\/doi.org\/10.1016\/0002-9343(87)90762-5","journal-title":"Am J Med"},{"key":"7029_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/metabo13010027","volume":"13","author":"Y Ding","year":"2022","unstructured":"Ding Y, Fan S, Tang Y et al (2022) The Association between blood lipids and systemic lupus erythematosus: a two-sample mendelian randomization research. Metabolites 13:27. https:\/\/doi.org\/10.3390\/metabo13010027","journal-title":"Metabolites"},{"key":"7029_CR39","doi-asserted-by":"publisher","unstructured":"Zhang G, Cai Y, Liang J, et al. (2022) Causal relationships between rheumatism and dyslipidemia: a two-sample Mendelian randomization study. Front Endocrinol 13.https:\/\/doi.org\/10.3389\/fendo.2022.961505","DOI":"10.3389\/fendo.2022.961505"},{"key":"7029_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/09612033221090127","volume":"31","author":"MG Lang","year":"2022","unstructured":"Lang MG, Vinagre CGC, Bonfa E et al (2022) Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: a possible mechanism for the reversal of atherosclerosis in the disease. Lupus 31:659\u2013665. https:\/\/doi.org\/10.1177\/09612033221090127","journal-title":"Lupus"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07029-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:17:07Z","timestamp":1721823427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07029-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7029"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07029-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethical committee of the Zhongshan Hospital Xiamen University (2023\u2013105) and was carried out in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}